Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.79 |
| ▸ | CCNK | O75909 | 11/20 | 0.79 |
| ▸ | CDK12 | Q9NYV4 | 11/20 | 0.79 |
| ▸ | CDK9 | P50750 | 10/20 | 0.79 |
| ▸ | CDK7 | P50613 | 10/20 | 0.79 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.79 |
| ▸ | CCNH | P51946 | 8/20 | 0.79 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.79 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.79 |
| ▸ | MNAT1 | P51948 | 7/20 | 0.71 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.67 |
| ▸ | JUN | P05412 | 7/20 | 0.67 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29994490 | 0.90 | CDK2 (0.78) | CDK2CCNKCDK12CDK9CDK7 | |
| SCHEMBL6039764 | 0.90 | CDK2 (0.78) | CDK2CCNKCDK12CDK9CDK7 | |
| Hydrochloric Acid SCHEMBL17141264 | 0.89 | CDK2 (0.76) | CDK2CCNKCDK12CDK9CDK7 | |
| SCHEMBL21026860 | 0.89 | CCNK (0.72) | CDK2CCNKCDK12CDK9CDK7 | |
| SCHEMBL24839342 | 0.89 | CCNT1 (1.00) | CDK2CCNKCDK12CDK9CDK7 | |
| SCHEMBL17150597 | 0.89 | CDK7 (0.72) | CDK2CCNKCDK12CDK9CDK7 | |
| SCHEMBL29613489 | 0.89 | CCNT1 (1.00) | CDK2CCNKCDK12CDK9CDK7 | |
| SCHEMBL20190945 | 0.89 | CCNT1 (1.00) | CDK2CCNKCDK12CDK9CDK7 | |
| SCHEMBL20190942 | 0.89 | CCNT1 (1.00) | CDK2CCNKCDK12CDK9CDK7 | |
| SCHEMBL19054618 | 0.88 | CDK2 (0.72) | CDK2CCNKCDK12CDK9CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544971-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-11-07 | — | — | US | disclosed |
| EP-3489232-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| EP-3126352-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| WO-2015154039-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015154039-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK2 8/4885CCNK 6/4885CDK12 28/4885 |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK2 7/4885CCNK 8/4885CDK12 24/4885 |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | CDK2 10/4885CCNK 19/4885CDK12 3/4885 |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK2 8/4885CCNK 6/4885CDK12 28/4885 |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CDK2 8/4885CCNK 6/4885CDK12 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.